Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company’s chemistry, manufacturing and controls (CMC) strategy as it advances toward investigational new drug (IND)-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The effort will be conducted in collaboration with Dalton Pharma Services and is intended to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness and future clinical supply requirements.
For business and technology leaders, this announcement signals a critical transition from laboratory-scale research to commercial-ready production. The ability to manufacture ONC010 reliably and at scale is essential for regulatory approval and eventual market delivery. The partnership with Dalton Pharma Services, a contract development and manufacturing organization, leverages external expertise to accelerate process optimization, reducing time and risk.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours.
The advancement of ONC010 into process development underscores the company’s commitment to moving its pipeline forward. For the oncology industry, successful CMC development can shorten timelines to clinical trials and ultimately to patients. For investors, this milestone may de-risk the program by demonstrating manufacturing feasibility, a key factor in drug development valuation.
To view the full press release, visit https://nnw.fm/kfFWv. For more information about Onco-Innovations, go to https://oncoinnovations.com/.
